129 related articles for article (PubMed ID: 15491054)
1. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B.
Risovic V; Sachs-Barrable K; Boyd M; Wasan KM
Drug Dev Ind Pharm; 2004 Aug; 30(7):767-74. PubMed ID: 15491054
[TBL] [Abstract][Full Text] [Related]
2. Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus.
Risovic V; Rosland M; Sivak O; Wasan KM; Bartlett K
Drug Dev Ind Pharm; 2007 Jul; 33(7):703-7. PubMed ID: 17654018
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
4. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
5. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
6. Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.
Kwong EH; Ramaswamy M; Bauer EA; Hartsel SC; Wasan KM
Antimicrob Agents Chemother; 2001 Jul; 45(7):2060-3. PubMed ID: 11408223
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
8. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
9. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
10. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.
Vadiei K; Lopez-Berestein G; Luke DR
Int J Obes; 1990 Jun; 14(6):465-72. PubMed ID: 2401582
[TBL] [Abstract][Full Text] [Related]
11. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
Kennedy AL; Wasan KM
J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.
Wasan KM; Wasan EK; Hnik P
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816728
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of amphotericin B-cyclosporine interaction in the rat.
Langston JD; Wasan KM; Lopez-Berestein G; Verani RR; Luke DR
Transplantation; 1990 Sep; 50(3):506-10. PubMed ID: 2205957
[TBL] [Abstract][Full Text] [Related]
14. Differences in the method by which plasma is separated from whole blood influences amphotericin B plasma recovery and distribution following amphotericin B lipid complex incubation within whole blood.
Ramaswamy M; Wasan KM
Drug Dev Ind Pharm; 2001 Sep; 27(8):871-5. PubMed ID: 11699840
[TBL] [Abstract][Full Text] [Related]
15. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tissue distribution of an orally administered mucoadhesive chitosan-coated amphotericin B-Loaded nanostructured lipid carrier (NLC) in rats.
Tan JSL; Roberts C; Billa N
J Biomater Sci Polym Ed; 2020 Feb; 31(2):141-154. PubMed ID: 31612804
[TBL] [Abstract][Full Text] [Related]
17. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
[TBL] [Abstract][Full Text] [Related]
18. Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins.
Wasan KM; Lopez-Berestein G
Ann N Y Acad Sci; 1994 Aug; 730():93-106. PubMed ID: 8080218
[TBL] [Abstract][Full Text] [Related]
19. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.
Patankar N; Wasan KM
Pharm Res; 2006 May; 23(5):1020-4. PubMed ID: 16715392
[TBL] [Abstract][Full Text] [Related]
20. Does P-glycoprotein contribute to amphotericin B epithelial transport in Caco-2 cells?
Osei-Twum JA; Wasan KM
Drug Dev Ind Pharm; 2015; 41(7):1130-6. PubMed ID: 24963546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
